Core Viewpoint - Recently, Stone Pharmaceutical Group (01093) has seen a significant stock price increase due to a strategic partnership with AstraZeneca for the development and commercialization of eight innovative long-acting peptide drug projects outside of mainland China and Hong Kong/Macau [1] Group 1: Financial Details - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in cumulative milestone payments for development and sales [1] - The subsidiary of Giant Bio (New Nuo Wei, 300765) is entitled to receive 35% of the upfront payment and subsequent milestone payments based on actual conditions [1] Group 2: Future Prospects - CICC anticipates that by 2025, the company will have achieved external licensing for oral small molecule GLP-1 ($120 million upfront), AstraZeneca strategic cooperation ($110 million upfront), irinotecan liposome ($15 million upfront), and ROR1ADC ($15 million upfront) [1] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC/SiRNA series, which are expected to continue generating external licensing opportunities and milestone revenue recognition [1]
石药集团早盘涨超5% 此前与阿斯利康达成重磅合作 公司对外授权持续兑现